May. 21 at 2:32 PM
$CTXR some clowns getting very nervous here....don´t do this...don´t to that...lmao!
H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Citius Pharmaceuticals (CTXR) with a Buy rating and
$4 price target The company’s lead asset, Lymphir, is approved for the treatment of relapsed or refractory stage I-III cutaneous T-cell lymphoma, the analyst tells investors in a research note. The firm believes the early launch metrics are encouraging, including nearly 100% commercial lives covered, 83% of target accounts on formulary or in active review, and an initial European shipment via an international distribution partner.
